Susquehanna Fundamental Investments’s Karyopharm Therapeutics KPTI Stock Holding History

Susquehanna Fundamental Investments’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$461K	Hold	4,170	–	–	0.01%	1109
2021 Q4	$402K	Sell	4,170 -5,448	-57%	-$543K	0.01%	998
2021 Q3	$840K	Buy	9,618 +4,170	+77%	+$433K	0.02%	945
2021 Q2	$843K	Buy	5,448 +4,209	+340%	+$611K	0.02%	928
2021 Q1	$195K	Buy	+1,239	New	+$261K	﹤0.01%	1396
2020 Q4	–	Sell	-1,694	Closed	-$371K	–	1555
2020 Q3	$371K	Buy	+1,694	New	+$414K	0.01%	986

Other funds holding KPTI

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ITP

Iron Triangle Partners Cos Cob, Connecticut $875M AUM 49.85% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Susquehanna Fundamental Investments's KPTI Position: Q1 2022 in Review

Susquehanna Fundamental Investments held its Karyopharm Therapeutics (KPTI) position steady in Q1 2022 at 4,170 shares worth $461K. The position accounts for 0.01% of the portfolio, ranked #1109.

Susquehanna Fundamental Investments first reported a position in KPTI in Q3 2020 and has held it in 6 quarters since. The position peaked at $843K in Q2 2021. 139 funds tracked by Wall St. Rank hold KPTI as of Q1 2022.

Susquehanna Fundamental Investments held 4,170 shares of Karyopharm Therapeutics worth $461K as of Q1 2022.
Susquehanna Fundamental Investments left its Karyopharm Therapeutics share count unchanged in Q1 2022.
Karyopharm Therapeutics made up 0.01% of Susquehanna Fundamental Investments's portfolio in Q1 2022, its #1109 holding.
Susquehanna Fundamental Investments first reported a position in Karyopharm Therapeutics in Q3 2020 and has held it in 6 quarters since.
Susquehanna Fundamental Investments's Karyopharm Therapeutics position peaked at $843K in Q2 2021.
139 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2022, filed 16 May 2022.